## Protocol Section
### Identification Module
**NCT ID:** NCT06425549

**Acronym:** BE TOGETHER

**Brief Title:** A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

**Official Title:** A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

#### Organization Study ID Info
**ID:** PS0021
#### Organization
**Class:** INDUSTRY
**Full Name:** UCB Pharma
#### Secondary ID Infos
**Domain:** WHO universal trial number (UTN)
**ID:** U1111-1293-2383
**Type:** OTHER
**Domain:** CTIS (EU CT)
**ID:** 2023-503859-10-00
**Type:** REGISTRY
### Status Module
#### Completion Date
**Date:** 2030-11-08

**Type:** ESTIMATED

#### Last Update Post Date
**Date:** 2024-05-22

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-17

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2028-08-21

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-05

**Type:** ESTIMATED

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-22
**Type:** ACTUAL
**Study First Submit Date:** 2024-05-02
**Study First Submit QC Date:** 2024-05-17
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** UCB Biopharma SRL

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).

### Conditions Module

**Conditions:**

- Moderate to Severe Plaque Psoriasis

**Keywords:**

- bimekizumab

- BKZ

- ustekinumab

- paediatric study participants

- children

- adolescents

- Psoriasis

- PSO

- Plaque Psoriasis

- Paediatric Psoriasis

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** QUADRUPLE

**Who Masked:**

- PARTICIPANT

- CARE_PROVIDER

- INVESTIGATOR

- OUTCOMES_ASSESSOR

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 168

**Type:** ESTIMATED

**Phases:**

- PHASE3

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Study participants randomized to this arm receive bimekizumab dosage regimen 1 at pre-specified timepoints during the Initial Treatment Period (16 weeks). They continue to receive bimekizumab dosage regimen 2 in the Maintenance Period (32 weeks). Under certain conditions study participants may be offered to continue on bimekizumab dosage regimen 2 in the Open-label Extension (OLE) Period (104 weeks).

**Intervention Names:**

- Drug: bimekizumab

- Drug: placebo

**Label:** bimekizumab

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Study participants randomized to this arm receive ustekinumab at pre-specified timepoints during the Initial Treatment Period (16 weeks) and during the Maintenance Period. Under certain conditions participants may switch to bimekizumab dosage regimen 1 (16 weeks) and continue with bimekizumab dosage regimen 2 in the last 16 weeks of the Maintenance Period. Under certain conditions study participants may be offered to participate in the OLE Period also receiving bimekizumab dosage regimen 2.

**Intervention Names:**

- Drug: bimekizumab

- Drug: ustekinumab

- Drug: placebo

**Label:** ustekinumab

**Type:** ACTIVE_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- bimekizumab

- ustekinumab

**Description:** Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.

**Name:** bimekizumab

**Other Names:**

- BKZ

- UCB4940

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- ustekinumab

**Description:** Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.

**Name:** ustekinumab

**Other Names:**

- USTE

**Type:** DRUG

#### Intervention 3

**Arm Group Labels:**

- bimekizumab

- ustekinumab

**Description:** Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.

**Name:** placebo

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

**Measure:** Psoriasis Area Severity Index 90 (PASI90) response at Week 16

**Time Frame:** Week 16

**Description:** The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.

IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline.

**Measure:** Investigator´s Global Assessment (IGA) 0/1 response at Week 16

**Time Frame:** Week 16

#### Secondary Outcomes

**Description:** The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

**Measure:** PASI75 response at Week 4

**Time Frame:** Week 4

**Description:** A PASI100 responder is defined as a subject that achieves 100% reduction from Baseline in the PASI score. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

**Measure:** PASI100 response at Week 16

**Time Frame:** Week 16

**Description:** The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

**Measure:** PASI90 response at Week 48

**Time Frame:** Week 48

**Description:** The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.

IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline.

**Measure:** IGA 0/1 response at Week 48

**Time Frame:** Week 48

**Description:** A PASI100 responder is defined as a subject that achieves 100% reduction from Baseline in the PASI score. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

**Measure:** PASI100 response at Week 48

**Time Frame:** Week 48

**Description:** The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.

IGA 0 response (Clear) is defined as clear \[0\] with at least a two-category improvement from Baseline.

**Measure:** IGA 0 response at Week 16

**Time Frame:** Week 16

**Description:** The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild, just detectable to mild thickening; pink to light red coloration; predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and 4= severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.

IGA 0 response (Clear) is defined as clear \[0\] with at least a two-category improvement from Baseline.

**Measure:** IGA 0 response at Week 48

**Time Frame:** Week 48

**Description:** An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.

**Measure:** Incidence of treatment-emergent adverse events (TEAE)s

**Time Frame:** From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

**Description:** An serious adverse event (SAE) must meet 1 or more of the following criteria:

* Results in death
* Is life-threatening
* Requires inpatient hospitalization or prolongation of existing hospitalization
* Results in persistent disability/incapacity
* Is a congenital anomaly/birth defect
* Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious.

Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.

**Measure:** Incidence of serious TEAEs

**Time Frame:** From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

**Description:** An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks. This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason.

**Measure:** Incidence of TEAEs leading to discontinuation of Investigational Medicinal Product (IMP)

**Time Frame:** From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

**Description:** An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks. This measure considers any TEAE leading to permanent withdrawal from study.

**Measure:** Incidence of TEAEs leading to withdrawal from the study

**Time Frame:** From Baseline (Week 0) to End of Safety Follow-up (up to Week 164)

**Description:** Safety topics of interest are infections (serious, opportunistic, fungal, and tuberculosis), inflammatory bowel disease, and injection site reactions.

**Measure:** Incidence of TEAEs predefined as safety topics of interest

**Time Frame:** From Baseline (Week 0) to Week 48 and to End of Safety Follow-up (up to Week 164)

**Description:** Blood pressure will be measured in millimeters of mercury (mmHg).

**Measure:** Change from Baseline in vital signs (systolic blood pressure)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Blood pressure will be measured in millimeters of mercury (mmHg).

**Measure:** Change from Baseline in vital signs (diastolic blood pressure)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Pulse rate will be measured in beats per minute (beats/min).

**Measure:** Change from Baseline in vital signs (pulse rate)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Clinically significant findings or worsening of previous findings since the physical examination at Baseline will be reported as TEAEs.

**Measure:** Incidence of clinically significant physical examination findings reported as TEAEs

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Growth assessment, as assessed by the change from Baseline in height.

**Measure:** Change from Baseline in height (growth assessment)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Growth assessment, as assessed by the change from Baseline in weight.

**Measure:** Change from Baseline in weight (growth assessment)

**Time Frame:** From Baseline (Week 0) up to Week 48.

**Description:** Platelets will be measured in number of platelets per liter (10\^9/L).

**Measure:** Change from Baseline in hematology parameters (platelet count)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Erythrocytes will be measured in number of red blood cells per liter (10\^12/L).

**Measure:** Change from Baseline in hematology parameters (erythrocytes)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Hemoglobin will be measured in grams per liter (g/L).

**Measure:** Change from Baseline in hematology parameters (hemoglobin)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Hematocrit will be measured in volume percentage (%) of red blood cells in blood.

**Measure:** Change from Baseline in hematology parameters (hematocrit)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma-glutamyltransferase will be measured in units per liter (U/L).

**Measure:** Change from Baseline in biochemistry parameters (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes will be measured in number of white blood cells per liter (10\^9/L).

**Measure:** Change from Baseline in hematology parameters (basophils, eosinophils, lymphocytes, monocytes, neutrophils, leukocytes)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Glucose, potassium, sodium and calcium will be measured in millimoles per liter (mmol/L).

**Measure:** Change from Baseline in biochemistry parameters (glucose, potassium, sodium, calcium)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** Clinical chemistry parameters will be measured in micromols per liter (μmol/L).

**Measure:** Change from Baseline in biochemistry parameters (total bilirubin and direct bilirubin, total protein, blood urea nitrogen, and creatinine)

**Time Frame:** From Baseline (Week 0) up to Week 48

**Description:** The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week. The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).

**Measure:** Change from Baseline in Children's Dermatology Life Quality Index (CDLQI) total score at Week 16

**Time Frame:** Week 16, compared to Baseline

**Description:** The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week. The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).

**Measure:** Change from Baseline in Children's Dermatology Life Quality Index (CDLQI) total score at Week 48

**Time Frame:** Week 48, compared to Baseline

**Description:** The CHAQ is a questionnaire designed to capture physical function in children and adolescents with juvenile rheumatoid arthritis. The CHAQ comprises 2 indices, Disability and Discomfort. The Disability Index assesses the degree of difficulty experienced over the past week across 30 items in the following 8 categories of the daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. The Disability Index ranges from 0 (no disability) to 3 (maximum disability). Discomfort is determined by the presence of pain, as measured by a 100-mm visual analogue scale (VAS). In addition, a final global assessment item asks study participants to rate how they are doing by placing a mark on a 100 mm VAS.

**Measure:** Change from Baseline in Childhood Health Assessment Questionnaire (CHAQ) disability index at Week 16 for study participants with juvenile PsA prior to Baseline

**Time Frame:** Week 16, compared to Baseline

**Description:** The Peak Pruritus NRS measures the worst level of itching in the past 24 hours on an 11-point scale ranging from 0 (no itch) to 10 (worst imaginable itch).

**Measure:** Change from Baseline in Peak Pruritus numerical rating scale (NRS) score at Week 16

**Time Frame:** Week 16, compared to Baseline

**Description:** Plasma bimekizumab concentrations prior to investigational medicinal product (IMP) administration and following investigational medicinal product (IMP) administration

**Measure:** Plasma bimekizumab concentrations prior to and following IMP administration over the Initial Treatment Period, over the Maintenance Period, and over the OLE Period

**Time Frame:** From Baseline to End of OLE Period (up to 144 weeks)

**Description:** Anti-bimekizumab antibody (AbAb) detection prior to investigational medicinal product (IMP) administration and following investigational medicinal product (IMP) administration

**Measure:** Plasma anti-bimekizumab antibodies prior to and following IMP administration over the Initial Treatment Period, over the Maintenance Period, and over the OLE Period

**Time Frame:** From Baseline to End of OLE Period (up to 144 weeks)

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Study participant must be 6 to \<18 years of age, inclusive, at the time of signing the informed consent/assent according to local regulation
* Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit
* Study participant meets the following at both the Screening and Baseline Visits:

  1. Body surface area (BSA) affected by PSO ≥10%
  2. . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
  3. . Psoriasis Area and Severity Index (PASI) score ≥12 OR

PASI score ≥10 plus at least 1 of the following:

i) Clinically relevant facial involvement ii) Clinically relevant genital involvement iii) Clinically relevant hand and foot involvement

* Study participant is a candidate for systemic PSO therapy and/or photo/chemotherapy and for treatment with ustekinumab per labeling
* Study participant has body weight ≥15 kg and body mass index for age percentile of ≥5 at Screening

Exclusion Criteria:

* Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier other than an IL-17
* Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
* Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
* History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
* Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
* Study participant has previously received bimekizumab
* Study participant has previously received ustekinumab
* Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments
* Study participant has the presence of active suicidal ideation, or positive suicide behavior
* Study participant diagnosed with severe depression in the past 6 months (prior to Screening) should be excluded
* Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study

**Maximum Age:** 17 Years

**Minimum Age:** 6 Years

**Sex:** ALL

**Standard Ages:**

- CHILD

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** ucbcares@ucb.com

**Name:** UCB Cares

**Phone:** 1-844-599-2273 (USA)

**Role:** CONTACT

**Contact 2:**

**Email:** UCBCares@ucb.com

**Name:** UCB Cares

**Phone:** 001 844 599 2273

**Role:** CONTACT

#### Overall Officials

**Official 1:**

**Affiliation:** 001 844 599 2273

**Name:** UCB Cares

**Role:** STUDY_DIRECTOR

### IPD Sharing Statement Module

**Access Criteria:** Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

**Description:** Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

**Info Types:**

- STUDY_PROTOCOL

- SAP

- CSR

**IPD Sharing:** YES

**Time Frame:** Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

**URL:** https://Vivli.org

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000017444

- Term: Skin Diseases, Papulosquamous

- ID: D000012871

- Term: Skin Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC17

- Name: Skin and Connective Tissue Diseases

- Abbrev: All

- Name: All Conditions

### Condition Browse Module - Browse Leaves

- ID: M14422

- Name: Psoriasis

- Relevance: HIGH

- As Found: Psoriasis

- ID: M15674

- Name: Skin Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M19713

- Name: Skin Diseases, Papulosquamous

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000011565

- Term: Psoriasis

### Intervention Browse Module - Ancestors

- ID: D000003879

- Term: Dermatologic Agents

### Intervention Browse Module - Browse Branches

- Abbrev: Derm

- Name: Dermatologic Agents

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: CNSDep

- Name: Central Nervous System Depressants

- Abbrev: Ot

- Name: Other Dietary Supplements

### Intervention Browse Module - Browse Leaves

- ID: M460

- Name: Ustekinumab

- Relevance: HIGH

- As Found: Manufactured

- ID: M4854

- Name: Benzocaine

- Relevance: LOW

- As Found: Unknown

- ID: M7074

- Name: Dermatologic Agents

- Relevance: LOW

- As Found: Unknown

- ID: T433

- Name: Tannic Acid

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: D000069549

- Term: Ustekinumab

### Misc Info Module

- Version Holder: 2024-05-31
